Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma

DSpace/Manakin Repository

Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma

Citable link to this page

 

 
Title: Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma
Author: ELLINGSON, BENJAMIN M.; KIM, EUNHEE; WOODWORTH, DAVIS C.; MARQUES, HELGA; BOXERMAN, JERROLD L.; SAFRIEL, YAIR; McKINSTRY, ROBERT C.; BOKSTEIN, FELIX; JAIN, RAJAN; CHI, T. LINDA; SORENSEN, A. GREGORY; GILBERT, MARK R.; BARBORIAK, DANIEL P.

Note: Order does not necessarily reflect citation order of authors.

Citation: ELLINGSON, B. M., E. KIM, D. C. WOODWORTH, H. MARQUES, J. L. BOXERMAN, Y. SAFRIEL, R. C. McKINSTRY, et al. 2015. “Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.” International Journal of Oncology 46 (5): 1883-1892. doi:10.3892/ijo.2015.2891. http://dx.doi.org/10.3892/ijo.2015.2891.
Full Text & Related Files:
Abstract: Functional diffusion mapping (fDM) is a cancer imaging technique that quantifies voxelwise changes in apparent diffusion coefficient (ADC). Previous studies have shown value of fDMs in bevacizumab therapy for recurrent glioblastoma multiforme (GBM). The aim of the present study was to implement explicit criteria for diffusion MRI quality control and independently evaluate fDM performance in a multicenter clinical trial (RTOG 0625/ACRIN 6677). A total of 123 patients were enrolled in the current multicenter trial and signed institutional review board-approved informed consent at their respective institutions. MRI was acquired prior to and 8 weeks following therapy. A 5-point QC scoring system was used to evaluate DWI quality. fDM performance was evaluated according to the correlation of these metrics with PFS and OS at the first follow-up time-point. Results showed ADC variability of 7.3% in NAWM and 10.5% in CSF. A total of 68% of patients had usable DWI data and 47% of patients had high quality DWI data when also excluding patients that progressed before the first follow-up. fDM performance was improved by using only the highest quality DWI. High pre-treatment contrast enhancing tumor volume was associated with shorter PFS and OS. A high volume fraction of increasing ADC after therapy was associated with shorter PFS, while a high volume fraction of decreasing ADC was associated with shorter OS. In summary, DWI in multicenter trials are currently of limited value due to image quality. Improvements in consistency of image quality in multicenter trials are necessary for further advancement of DWI biomarkers.
Published Version: doi:10.3892/ijo.2015.2891
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383029/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:15035046
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters